Growth DisordersECROIPEDNCT07026812
Impact of Screens on Children's Growth
An observational study of Growth Disorders, run by University Hospital, Rouen at 1 site in France.
Trial summary
Short stature is defined as a height less than -2 Standard Deviations (SD) for age and a slowing of growth velocity by a loss of 1 SD/year. The causes of short stature are multiple (chronic diseases, growth hormone deficiency, hypothyroidism, hyperadrenocorticism, genetic syndromes, etc.). Read more about this study
- Who is it for?
- Ages 6 to 16 years
- Conditions the study is for
- Growth Disorders
- How many people
- 150 participants
- Where
- 1 siteFrance
- Study dates
- 26 Sep 2022to 1 Jun 2025
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 16 years
- All sexes
- No healthy volunteers
- Child
Study population: Any patient coming to the day hospital for a growth hormone stimulation test and/or for an oral provocation test in the context of an allergy,
Who may be able to join
- Children aged 6 to 16 years old coming to the day hospital for a growth hormone stimulation test or an oral provocation test (without growth disorders)
- Not opposed to participating in the study
- Patients affiliated with the Social Security system
Who cannot join
- Growth hormone deficiency confirmed by 2 tests
- Hypothyroidism
- Hypercorticism
- All chronic diseases
- Skeletal pathologies: Turner syndrome, constitutional bone disease Intrauterine growth retardation
- Pubertal delay defined by absence of puberty onset >13 years in girls and 14 years in boys
- Patient under guardianship
Trial locations and contacts
1 site in 1 country.
About this study
Short stature is defined as a height less than -2 Standard Deviations (SD) for age and a slowing of growth velocity by a loss of 1 SD/year. The causes of short stature are multiple (chronic diseases, growth hormone deficiency, hypothyroidism, hyperadrenocorticism, genetic syndromes, etc.). However, nearly 30% are considered idiopathic, with no identified etiology (Naccache et al., unpublished).
Growth hormone (GH) is secreted in a pulsatile manner with maximum peaks primarily at night, raising questions about the relationship between sleep disturbances and short stature.
In children, one of the main causes of sleep disturbances in the digital age is screen use, which is becoming increasingly important, particularly in the pediatric population.
Read the detailed description
During the night, physiologically, the retina, which no longer receives light signals, sends a message to the suprachiasmatic nucleus, the main key element of the internal clock, and to the pineal gland, which synthesizes melatonin, the sleep hormone. Exposing screens to blue light therefore disrupts melatonin secretion, which leads to a disruption of the circadian rhythm and therefore sleep. Note that this effect of light on melatonin secretion depends on the time of day of exposure, the intensity, and the duration. Thus, exposure to screens before bedtime can be responsible for a delay or even an absence of melatonin synthesis, particularly in the case of nighttime awakenings.
While many studies have examined the impact of screens on children's psychological balance, weight, etc., none, to our knowledge, has examined the potential impact of screens on children's height growth. Hypothesis of this project: 70% of GH synthesis takes place at night, a few minutes after entering slow-wave sleep, sleep disturbed by screens could mean a lower secretion of GH and consequently a delay in height growth.
The objective of this project is to evaluate the impact of screen consumption on sleep and the impact of sleep on idiopathic growth disorder.
- Conditions
- Growth Disorders
- Keywords
- Growth hormone
- Medical subject headings
- Growth Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Growth hormone stimulation test group | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Screen consumption on sleep
Evaluation of the Impact of Screen Consumption on Sleep by Answers to the Questionnaire Given to the Child and/or Parent(s) (Depending on Age)
Measured: At enrollment visit
Screen consumption on sleep
Sleep assessment by responses to the questionnaire given to the child and/or the parent(s) (depending on age) in order to assess the duration of sleep
Measured: At enrollment visit
Screen consumption on sleep
Evaluation of the Impact of Screen Consumption on Sleep by Answers to the Questionnaire Given to the Child and/or Parent(s) (Depending on Age) in Order to Evaluate child's physical activity
Measured: At enrollment visit
Impact of sleep on idiopathic growth disorder
Collection of auxological data at the time of the day hospital consultation (height) noted in the health record and/or in the hospital medical file
Measured: At enrollment visit
Impact of sleep on idiopathic growth disorder
Collection of auxological data at the time of the day hospital consultation (weight) noted in the health record and/or in the hospital medical file
Measured: At enrollment visit
Impact of sleep on idiopathic growth disorder
Collection of auxological data at the time of the day hospital consultation (age) noted in the health record and/or in the hospital medical file
Measured: At enrollment visit
Secondary outcomes (1)
Impact of screens on body size (BMI)
Evaluation of the impact of screens on body size (BMI) by response to the questionnaire given to the child and/or the parent(s)
Measured: At enrollment visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jun 2025
- Study start26 Sep 2022
- Primary completion11 Sep 2024
- Study completion1 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Growth DisordersStudies of the same condition, open and under way.
- More trials run by University Hospital, RouenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 150 participants (actual)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- University Hospital, Rouen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Mireille MC CASTANET, Professor, Principal investigator, University Hospital, RouenMireille MC CASTANET, Professor, Study director, University Hospital, Rouen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07026812
- Sponsor's protocol ID
- 2021/138/OB
- Other IDs
- ID RCB : 2021-A01115-36
- Acronym
- ECROIPED
- Status last verified
- Jan 2025
- First submitted
- 10 Jun 2025
- Last updated
- 18 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The data provided will be the property of the sponsor and will be used solely for its own research activities.
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Screens on Children's Growth
- ClinicalTrials.gov ID
- NCT07026812
- Acronym / sponsor ID
- ECROIPED / 2021/138/OB
- Conditions
- Growth Disorders
- Keywords
- Growth hormone
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 150 participants (actual)
- Lead sponsor
- University Hospital, RouenUniversity, hospital or other
- Study start
- 26 Sep 2022 (actual)
- Primary completion
- 11 Sep 2024 (actual)
- Study completion
- 1 Jun 2025 (actual)
- First posted
- 18 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Short stature is defined as a height less than -2 Standard Deviations (SD) for age and a slowing of growth velocity by a loss of 1 SD/year. The causes of short stature are multiple (chronic diseases, growth hormone deficiency, hypothyroidism, hyperadrenocorticism, genetic syndromes, etc.). However, nearly 30% are considered idiopathic, with no identified etiology (Naccache et al., unpublished).
Growth hormone (GH) is secreted in a pulsatile manner with maximum peaks primarily at night, raising questions about the relationship between sleep disturbances and short stature.
In children, one of the main causes of sleep disturbances in the digital age is screen use, which is becoming increasingly important, particularly in the pediatric population.
Detailed description
During the night, physiologically, the retina, which no longer receives light signals, sends a message to the suprachiasmatic nucleus, the main key element of the internal clock, and to the pineal gland, which synthesizes melatonin, the sleep hormone. Exposing screens to blue light therefore disrupts melatonin secretion, which leads to a disruption of the circadian rhythm and therefore sleep. Note that this effect of light on melatonin secretion depends on the time of day of exposure, the intensity, and the duration. Thus, exposure to screens before bedtime can be responsible for a delay or even an absence of melatonin synthesis, particularly in the case of nighttime awakenings.
While many studies have examined the impact of screens on children's psychological balance, weight, etc., none, to our knowledge, has examined the potential impact of screens on children's height growth. Hypothesis of this project: 70% of GH synthesis takes place at night, a few minutes after entering slow-wave sleep, sleep disturbed by screens could mean a lower secretion of GH and consequently a delay in height growth.
The objective of this project is to evaluate the impact of screen consumption on sleep and the impact of sleep on idiopathic growth disorder.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 1 Day
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Growth hormone stimulation test group | – | – |
Who may qualify
- Ages
- 6 to 16 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Any patient coming to the day hospital for a growth hormone stimulation test and/or for an oral provocation test in the context of an allergy,
Key inclusion criteria (3 listed)
- Children aged 6 to 16 years old coming to the day hospital for a growth hormone stimulation test or an oral provocation test (without growth disorders)
- Not opposed to participating in the study
- Patients affiliated with the Social Security system
Key exclusion criteria (7 listed)
- Growth hormone deficiency confirmed by 2 tests
- Hypothyroidism
- Hypercorticism
- All chronic diseases
- Skeletal pathologies: Turner syndrome, constitutional bone disease Intrauterine growth retardation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Screen consumption on sleep
Time frame: At enrollment visit
Evaluation of the Impact of Screen Consumption on Sleep by Answers to the Questionnaire Given to the Child and/or Parent(s) (Depending on Age)
Screen consumption on sleep
Time frame: At enrollment visit
Sleep assessment by responses to the questionnaire given to the child and/or the parent(s) (depending on age) in order to assess the duration of sleep
Screen consumption on sleep
Time frame: At enrollment visit
Evaluation of the Impact of Screen Consumption on Sleep by Answers to the Questionnaire Given to the Child and/or Parent(s) (Depending on Age) in Order to Evaluate child's physical activity
Impact of sleep on idiopathic growth disorder
Time frame: At enrollment visit
Collection of auxological data at the time of the day hospital consultation (height) noted in the health record and/or in the hospital medical file
Impact of sleep on idiopathic growth disorder
Time frame: At enrollment visit
Collection of auxological data at the time of the day hospital consultation (weight) noted in the health record and/or in the hospital medical file
Impact of sleep on idiopathic growth disorder
Time frame: At enrollment visit
Collection of auxological data at the time of the day hospital consultation (age) noted in the health record and/or in the hospital medical file
1 secondary outcome
Impact of screens on body size (BMI)
Time frame: At enrollment visit
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2025.
- Individual participant dataSharing planned: No. The data provided will be the property of the sponsor and will be used solely for its own research activities.
Related trials for Growth Disorders
Recruiting
Short-Term Reduced Dietary Protein in ER+/HER2- Breast Cancer Patients During Neoadjuvant Chemotherapy
Breast Cancer, Hormone Receptor Positive / HER2-negative Breast Cancer
RecruitingPhase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Breast Neoplasms, Breast Cancer
RecruitingPhase 1/2
A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
EGFR-Mutant Non-Small Cell Lung Cancer
Active, not recruitingPhase 2
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
Not yet recruitingPhase 3
Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.
Androgenetic Alopecia, Androgenetic Alopecia (AGA)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mireille MC CASTANET, Professor principal investigator
University Hospital, Rouen
Mireille MC CASTANET, Professor study director
University Hospital, Rouen
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Growth Disorders, run by University Hospital, Rouen at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Screen consumption on sleep (time frame: At enrollment visit). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2025.